MedPath

Aquinox Pharmaceuticals (Canada), Inc.

🇨🇦Canada
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

17

Active:8
Completed:7

Trial Phases

3 Phases

Phase 1:10
Phase 2:4
Phase 3:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials

Phase 1
10 (62.5%)
Phase 2
4 (25.0%)
Phase 3
2 (12.5%)

Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Phase 2
Terminated
Conditions
Chronic Prostatitis
Chronic Pelvic Pain Syndrome
Interventions
First Posted Date
2018-04-17
Last Posted Date
2019-01-09
Lead Sponsor
Aquinox Pharmaceuticals (Canada) Inc.
Target Recruit Count
3
Registration Number
NCT03500159
Locations
🇺🇸

Site 1026, Homewood, Alabama, United States

🇺🇸

Site 1010, Mobile, Alabama, United States

🇺🇸

Site 1004, Tucson, Arizona, United States

and more 24 locations

Oral AQX-1125 and Combination Oral Contraceptive Drug-Drug Interaction Study

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
Drug: Combined Oral Contraceptive
First Posted Date
2018-03-27
Last Posted Date
2018-06-13
Lead Sponsor
Aquinox Pharmaceuticals (Canada) Inc.
Target Recruit Count
32
Registration Number
NCT03478020
Locations
🇳🇱

PRA Health Sciences - Early Development Serices, Groningen, Netherlands

Phase 1 Absorption Distribution Metabolism and Excretion of AQX-1125

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
Drug: [14C]-AQX-1125 IV
Drug: [14C]-AQX-1125 Oral Solution
First Posted Date
2017-06-14
Last Posted Date
2017-06-14
Lead Sponsor
Aquinox Pharmaceuticals (Canada) Inc.
Target Recruit Count
9
Registration Number
NCT03185195
Locations
🇬🇧

Quotient Clinical, Nottingham, United Kingdom

Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome

Phase 3
Conditions
Chronic Interstitial Cystitis
Interstitial Cystitis
Bladder Pain Syndrome
Painful Bladder Syndrome
Interventions
First Posted Date
2016-08-08
Last Posted Date
2018-03-15
Lead Sponsor
Aquinox Pharmaceuticals (Canada) Inc.
Target Recruit Count
433
Registration Number
NCT02858453
Locations
🇺🇸

Site 9035, Homewood, Alabama, United States

🇺🇸

Site 9026, Tucson, Arizona, United States

🇺🇸

Site 9064, Little Rock, Arkansas, United States

and more 116 locations

Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: Placebo
First Posted Date
2014-12-24
Last Posted Date
2018-10-05
Lead Sponsor
Aquinox Pharmaceuticals (Canada) Inc.
Target Recruit Count
54
Registration Number
NCT02324972
Locations
🇨🇦

AQX-Innovaderm site, Montreal, Quebec, Canada

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.